Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target lowered by analysts at HC Wainwright from $29.00 to $28.00. They now have a "buy" rating on the stock.
Cullinan Oncology, Inc. (NASDAQ: CGEM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer